These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35413886)

  • 1. The effect of a loading dose of meropenem on outcomes of patients with sepsis treated by continuous renal replacement: study protocol for a randomized controlled trial.
    Ni SQ; Teng WB; Fu YH; Su W; Yang Z; Cai J; Xu JN; Deng XY; Liu XF; Fu SN; Zeng J; Zhang C
    Trials; 2022 Apr; 23(1):294. PubMed ID: 35413886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
    Peng Y; Cheng Z; Xie F
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
    Wang Y; Li Z; Chen W; Yan G; Wang G; Lu G; Chen C
    J Clin Pharm Ther; 2021 Jun; 46(3):754-761. PubMed ID: 33476064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
    Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
    Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
    J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
    Hagel S; Fiedler S; Hohn A; Brinkmann A; Frey OR; Hoyer H; Schlattmann P; Kiehntopf M; Roberts JA; Pletz MW;
    Trials; 2019 Jun; 20(1):330. PubMed ID: 31171029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
    Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
    Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
    Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI.
    Chihara S; Ishigo T; Kazuma S; Matsumoto K; Morita K; Masuda Y
    Antibiotics (Basel); 2024 Aug; 13(8):. PubMed ID: 39200055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.
    Ulldemolins M; Vaquer S; Llauradó-Serra M; Pontes C; Calvo G; Soy D; Martín-Loeches I
    Crit Care; 2014 Jun; 18(3):227. PubMed ID: 25042938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.
    Jaruratanasirikul S; Thengyai S; Wongpoowarak W; Wattanavijitkul T; Tangkitwanitjaroen K; Sukarnjanaset W; Jullangkoon M; Samaeng M
    Antimicrob Agents Chemother; 2015; 59(6):2995-3001. PubMed ID: 25753628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem pharmacokinetic/pharmacodynamic target attainment and clinical response in ICU patients: A prospective observational study.
    Helset E; Cheng V; Sporsem H; Thorstensen C; Nordøy I; Gammelsrud KW; Hanssen G; Ponzi E; Lipman J; von der Lippe E
    Acta Anaesthesiol Scand; 2024 Apr; 68(4):502-511. PubMed ID: 38286568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock - rationale and design of a multicenter randomized controlled superiority trial.
    Roggeveen LF; Fleuren LM; Guo T; Thoral P; de Grooth HJ; Swart EL; Klausch TLT; van der Voort PHJ; Girbes ARJ; Bosman RJ; Elbers PWG
    Trials; 2019 Dec; 20(1):745. PubMed ID: 31852491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis.
    Pařízková RČ; Martínková J; Havel E; Šafránek P; Kaška M; Astapenko D; Bezouška J; Chládek J; Černý V
    Crit Care; 2021 Jul; 25(1):251. PubMed ID: 34274013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.